Related Experiment Video
Updated: Jul 22, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson's disease model
Dongdong Zhang1, Sheng Li2, Liyan Hou1,2
1School of Public Health, Dalian Medical University, Dalian, 116044, China.
Background:
Cognitive decline occurs frequently in Parkinson's disease (PD), which greatly decreases the quality of life of patients. However, the mechanisms remain to be investigated. Neuroinflammation mediated by overactivated microglia is a common pathological feature in multiple neurological disorders, including PD. This study is designed to explore the role of microglia in cognitive deficits by using a rotenone-induced mouse PD model.
Methods:
To evaluate the role of microglia in rotenone-induced cognitive deficits, PLX3397, an inhibitor of colony-stimulating factor 1 receptor, and minocycline, a widely used antibiotic, were used to deplete or inactivate microglia, respectively. Cognitive performance of mice among groups was detected by Morris water maze, objective recognition, and passive avoidance tests. Neurodegeneration, synaptic loss, α-synuclein phosphorylation, glial activation, and apoptosis were determined by immunohistochemistry and Western blot or immunofluorescence staining. The gene expression of inflammatory factors and lipid peroxidation were further explored by using RT-PCR and ELISA kits, respectively.
Results:
Rotenone dose-dependently induced cognitive deficits in mice by showing decreased performance of rotenone-treated mice in the novel objective recognition, passive avoidance, and Morris water maze compared with that of vehicle controls. Rotenone-induced cognitive decline was associated with neurodegeneration, synaptic loss, and Ser129-phosphorylation of α-synuclein and microglial activation in the hippocampal and cortical regions of mice. A time course experiment revealed that rotenone-induced microglial activation preceded neurodegeneration. Interestingly, microglial depletion by PLX3397 or inactivation by minocycline significantly reduced neuronal damage and α-synuclein pathology as well as improved cognitive performance in rotenone-injected mice. Mechanistically, PLX3397 and minocycline attenuated rotenone-induced astroglial activation and production of cytotoxic factors in mice. Reduced lipid peroxidation was also observed in mice treated with combined PLX3397 or minocycline and rotenonee compared with rotenone alone group. Finally, microglial depletion or inactivation was found to mitigate rotenone-induced neuronal apoptosis.
Conclusions:
Taken together, our findings suggested that microglial activation contributes to cognitive impairments in a rotenone-induced mouse PD model via neuroinflammation, oxidative stress, and apoptosis, providing novel insight into the immunopathogensis of cognitive deficits in PD.
Insights
Microglial activation drives cognitive decline in Parkinson's disease (PD). Inhibiting microglia improves cognitive function and reduces neuroinflammation and neuronal damage in a mouse model of PD.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Cognitive decline is a common and debilitating symptom in Parkinson's disease (PD).
- The underlying mechanisms of cognitive impairment in PD are not fully understood.
- Overactivated microglia and subsequent neuroinflammation are implicated in various neurological disorders, including PD.
Purpose of the Study:
- To investigate the role of microglia in cognitive deficits observed in a rotenone-induced mouse model of Parkinson's disease.
- To explore the therapeutic potential of targeting microglia for cognitive improvement in PD.
Main Methods:
- Utilized a rotenone-induced mouse model to mimic Parkinson's disease pathology.
- Administered PLX3397 (microglial inhibitor) and minocycline (antibiotic) to deplete or inactivate microglia.
- Assessed cognitive performance using behavioral tests (Morris water maze, objective recognition, passive avoidance).
- Quantified neurodegeneration, synaptic loss, alpha-synuclein phosphorylation, glial activation, apoptosis, inflammatory gene expression, and lipid peroxidation.
Main Results:
- Rotenone administration induced dose-dependent cognitive deficits, neurodegeneration, synaptic loss, and microglial activation in mice.
- Microglial activation was observed to precede neurodegeneration.
- Depletion or inactivation of microglia significantly ameliorated cognitive deficits, reduced neuronal damage, and attenuated alpha-synuclein pathology.
- Targeting microglia reduced neuroinflammation, oxidative stress, and neuronal apoptosis.
Conclusions:
- Microglial activation plays a critical role in mediating cognitive impairments in Parkinson's disease.
- Neuroinflammation, oxidative stress, and apoptosis driven by microglia contribute to PD-related cognitive deficits.
- Targeting microglial activation presents a potential therapeutic strategy for managing cognitive dysfunction in Parkinson's disease.

